Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Trabzanoflast

Source date not recordedAnalyse record ↗

Brain-penetrant NLRP3 inhibitor that has completed Phase 1 and is being prepared for neuroinflammatory-disease development.

Modality
oral brain-penetrant small-molecule NLRP3 inflammasome inhibitor
Availability (US)
Phase 1 healthy-volunteer study completed; Phase 2 neuroinflammation development is planned but not active
Biomarkers
safety, tolerability, pharmacokinetics, biodistribution, and central and peripheral inflammatory markers
Hallmark targeted
chronic inflammation, altered intercellular communication, neuroinflammation
Kind
investigational drug
Clinical trials
NL-OMON60655 — completed first-in-human Phase 1 study